A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease
A Pilot Study of Exendin-4 in Alzheimer s Disease
Sponsor: National Institute on Aging (NIA)
Terminated
AstraZeneca withdrew support for the study.
Other terminated trials from National Institute on Aging (NIA)
Listed as NCT01255163, this PHASE2 trial focuses on Alzheimer's Disease and Mild Cognitive Impairment and remains terminated or withdrawn. Sponsored by National Institute on Aging (NIA), it has been updated 8 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 3 earlier versions
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Feb 2017 — Mar 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute on Aging (NIA)
For direct contact, visit the study record on ClinicalTrials.gov .